AbbVie has submitted an application to the FDA for the approval of TrenibotE — the first-in-class botulinum toxin type E. The product demonstrates a record-fast onset of action (8 hours) and a short duration of effect (2-3 weeks), which may change the approach to initial injections in patients who have previously avoided neurotoxins.

Sample informed consent form for the administration of Botox.

Article coming soon This page is under preparation and will be available soon.  

On the correction of a gummy smile, mimic wrinkles, and age-related changes in the lower third of the face and neck, as well as combined techniques for the use of botulinum toxin type A.

On the correction of mimic wrinkles and age-related changes in the upper third of the face (forehead, glabella, eyebrows, eyes, nose) using botulinum toxin type A.

Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxin A) for the Treatment of Moderate to Severe Glabellar Lines.

Many people have noticed that lately the effect of Botox has become shorter. Previously, the results lasted about six months, but now only around three. Is it tolerance? Are cosmetologists diluting the product more? Has the composition of the drug changed?

Today, the professional market offers an entire family of botulinum toxin–containing drugs, but they are not “twins” and have different safety and efficacy profiles, as well as differences related to production, composition, and application protocols.

In recent years, botulinum toxin preparations have gained popularity as a means of smoothing out expression lines — wrinkles caused by excessive activity of the facial muscles. But is Botox really dangerous, and what do we actually know about it?

In recent years, a trend has emerged toward undergoing rejuvenating procedures at an early age. The reasoning behind this is quite simple: early rejuvenation helps delay aging. But is this really the case?